Review article: Progress of treatment in ANCA-associated vasculitis

Nephrology

Volumn 14, Issue 1, 2009, Pages 42-48

  Jayne, David ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

ANCA; Clinical trial; Consensus statement; Cyclophosphamide; Therapy; Vasculitis

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOGLOBULIN; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

AGING; ANCA ASSOCIATED VASCULITIS; B CELL DEPLETION; BONE MARROW SUPPRESSION; CELL SELECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; HUMAN; INFECTION; INFERTILITY; KIDNEY FAILURE; MICROSCOPIC POLYANGIITIS; NEUTROPENIA; NEUTROPENIC SEPSIS; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS; SIDE EFFECT; TREATMENT RESPONSE; VASCULITIS; WEGENER GRANULOMATOSIS;

ANIMALS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AZATHIOPRINE; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; VASCULITIS;

EID: 63149095577     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01101.x     Document Type: Review

References (66)

1. Fauci AS, Wolff SM, Johnson JS. Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med 1971 285 : 1493 6.
2. Lockwood CM, Pinching AJ, Sweny P et al. Plasma-exchange and immunosuppression in the treatment of fulminating immune-complex crescentic nephritis. Lancet 1977 1 : 63 7.
3. Mukhtyar C, Guillevin L, Cid MC et al. EULAR Recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2008 68 : 310 17.
4. Lapraik C, Watts R, Bacon P et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007 46 : 1615 16.
5. Xiao H, Heeringa P, Hu P et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002 110 : 955 63.
6. The Wegener's Etanercept Study Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005 352 : 351 61.
7. Walsh M, Chaudhry A, Jayne DR. Long-term follow-up of relapsing/refractory ANCA associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 2008 67 : 1322 7.
8. Walsh M, Jayne D. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: Past, present and future. Kidney Int 2007 72 : 676 82.
9. van der Woude FJ, Rasmussen N, Lobatto S et al. Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985 1 : 425 9.
10. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). BMJ 1958 2 : 265 70.
11. Leib ES, Restivo C, Paulus HE. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 1979 67 : 941 7.
12. Booth AD, Almond MK, Burns A et al. Outcome of ANCA-associated renal vasculitis: A 5-year retrospective study. Am J Kidney Dis 2003 41 : 776 84.
13. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998 9 : 842 52.
14. Chen M, Yu F, Zhang Y, Zhao MH. Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine (Baltimore) 2008 87 : 203 9.
15. Pagnoux C, Hogan SL, Chin H et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: Comparison of two independent cohorts. Arthritis Rheum 2008 58 : 2908 18.
16. Seo P, Min YI, Holbrook JT et al. Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005 52 : 2168 78.
17. Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003 349 : 36 44.
18. Jayne DR, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: Initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 1997 72 : 737 47.
19. Watts RA, Scott DG, Jayne DR et al. Renal vasculitis in Japan and the UK-are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant 2008 23 : 3928 31.
20. de Groot K, Adu D, Savage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: Meta-analysis and critical review. Nephrol Dial Transplant 2001 16 : 2018 27.
21. Aries PM, Lamprecht P, Gross WL. Rituximab in refractory Wegener's granulomatosis: Favorable or not? Am J Respir Crit Care Med 2006 173 : 815 16 author reply 816.
22. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005 257 : 540 48.
23. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005 52 : 262 8.
24. Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: Favourable but temporary response. Scand J Rheumatol 2005 34 : 229 32.
25. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006 54 : 2970 82.
26. Stasi R, Stipa E, Poeta GD, Amadori S, Newland AC, Provan D. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology 2006 45 : 1432 6.
27. Henes JC, Fritz J, Koch S et al. Rituximab for treatment-resistant extensive Wegener's granulomatosis-additive effects of a maintenance treatment with leflunomide. Clin Rheumatol 2007 26 : 1711 15.
28. Brihaye B, Aouba A, Pagnoux C, Cohen P, Lacassin F, Guillevin L. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: A study on 8 patients. Clin Exp Rheumatol 2007 25 : S23 7.
29. de Groot K, Jayne D. What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and systemic vasculitides. Clin Nephrol 2005 64 : 480 84.
30. Bolton WK, Sturgill BC. Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis. Am J Nephrol 1989 9 : 368 75.
31. Jayne DR, Gaskin G, Rasmussen N et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007 18 : 2180 88.
32. Specks U. Diffuse alveolar hemorrhage syndromes. Curr Opin Rheumatol 2001 13 : 12 17.
33. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992 35 : 1322 9.
34. De Groot K, Rasmussen N, Bacon PA et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005 52 : 2461 9.
35. Hu W, Liu C, Xie H, Chen H, Liu Z, Li L. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 2008 23 : 1307 12.
36. Slot MC, Tervaert JW, Boomsma MM, Stegeman CA. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 2004 51 : 269 73.
37. Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology (Oxford) 2006 45 : 724 9.
38. Popa ER, Stegeman CA, Abdulahad WH et al. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology (Oxford) 2007 46 : 1029 33.
39. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim- sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996 335 : 16 20.
40. Metzler C, Miehle N, Manger K et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 2007 46 : 1087 91.
41. Neumann I, Fuhrmann H, Fang IF, Jaeger A, Bayer P, Kovarik J. Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. Nephrol Dial Transplant 2008 23 : 3514 20.
42. Koukoulaki M, Jayne DR. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clin Pract 2006 102 : c100 7.
43. Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 2005 20 : 2725 32.
44. Martinez V, Cohen P, Pagnoux C et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: Results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 2008 58 : 308 17.
45. Boomsma MM, Stegeman CA, van der Leij MJ et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: A prospective study. Arthritis Rheum 2000 43 : 2025 33.
46. Tervaert JW, Huitema MG, Hene RJ et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990 336 : 709 11.
47. Jayne DR, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. QJM 1995 88 : 127 33.
48. Jayne D. Current attitudes to the therapy of vasculitis. Kidney Blood Press Res 2003 26 : 231 9.
49. Jayne DR, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: Initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 1997 72 : 737 47.
50. Hellmich B, Flossmann O, Gross WL et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: Focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007 66 : 605 17.
51. Jayne DR, Chapel H, Adu D et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000 93 : 433 9.
52. Booth A, Harper L, Hammad T et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004 15 : 717 21.
53. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety. Arthritis Rheum 2001 44 : 1149 54.
54. Birck R, Newman M, Braun C et al. 15-Deoxyspergualin and cyclophosphamide, but not mycophenolate mofetil, prolong survival and attenuate renal disease in a murine model of ANCA-associated crescentic nephritis. Nephrol Dial Transplant 2006 21 : 58 63.
55. Flossmann O, Baslund B, Bruchfeld A et al. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis 2008 [ePub ahead of print 19 Aug 2008].
56. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suarez LF, van der Woude FJ. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): An open study in 15 patients. Kidney Int 2004 65 : 1440 48.
57. Pepper RJ, Fabre MA, Pavesio C et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology 2008 47 : 1101 5.
58. Bayés M, Rabasseda X, Prous JR. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563. Drugs R D 2008 9 : 125 30.
59. Jayne D. Role of Rituximab Therapy in Glomerulonephritis. J Am Soc Nephrol 2008 [ePub ahead of print 15 Sep 2008].
60. Tam FW, Sanders JS, George A et al. Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol Dial Transplant 2004 19 : 2761 8.
61. Alcorta DA, Barnes DA, Dooley MA et al. Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis. Kidney Int 2007 72 : 853 64.
62. Schmitt WH, Heesen C, Csernok E, Rautmann A, Gross WL. Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. Arthritis Rheum 1992 35 : 1088 96.
63. Booth AD, Wallace S, McEniery CM et al. Inflammation and arterial stiffness in systemic vasculitis: A model of vascular inflammation. Arthritis Rheum 2004 50 : 581 8.
64. de Groot K, Goldberg C, Bahlmann FH et al. Vascular endothelial damage and repair in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2007 56 : 3847 53.
65. Woywodt A, Streiber F, de Groot K, Regelsberger H, Haller H, Haubitz M. Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 2003 361 : 206 10.
66. Brogan PA, Dillon MJ. Endothelial microparticles and the diagnosis of the vasculitides. Intern Med 2004 43 : 1115 19.